Hsu C.-S.JIA-HORNG KAO2021-09-042021-09-042012#VALUE!https://www.scopus.com/inward/record.uri?eid=2-s2.0-84895215140&partnerID=40&md5=b2cdc47fa1362c065405254022f9c483https://scholars.lib.ntu.edu.tw/handle/123456789/582035Existing lines of evidence have highlighted the beginning of a genomic era for the management of hepatitis C virus (HCV) infection. Several research groups from different countries using the approaches of genome-wide association studies (GWAS) simultaneously identified the polymorphism of IL28B gene as an important predictor of therapeutic response for chronic hepatitis C (CHC) patients receiving interferonbased treatment in 2009. Moreover, they also found that host genetic variations near IL28B gene also play an important role in the spontaneous clearance of HCV. On the other hand, inosine triphosphate pyrophosphatase (ITPA) gene variants are reported to affect ribavirininduced anemia and therapeutic outcomes in CHC patients. In this article, recent advances in genome-wide association studies regarding HCV infection, and their impacts on current management of CHC patients will be reviewed. In addition, the clinical usefulness of genomic variations on the addition of direct antiviral agents (DAAs) to current standard of care will be discussed. ? 2012 Nova Science Publishers, Inc. All rights reserved.Hepatitis C virus; IL28B SNP; Individualized therapy; Metabolic profiles; Pegylated interferon; Viral kinetics[SDGs]SDG3book part2-s2.0-84895215140